Matrivax is a privately held biotechnology company, located in Boston, Massachusetts, focused on the development of affordable vaccines to combat the global burden of bacterial disease.
Our pipeline includes vaccine candidates against Streptococcus pneumoniae, Clostridium difficile infection, and typhoid fever.
Matrivax has developed Typhax, a novel Protein Capsular Matrix Vaccine (PCMV), for the prevention of typhoid fever. Results from a Typhax Phase 1 clinical study showed the vaccine candidate is well tolerated and highly immunogenic in healthy human subjects.
We are excited to announce that Dr. Manon M.J. Cox, former President and CEO of Protein Sciences, is now the CEO of Matrivax.
Advance our universal S. pneumoniae and our C. difficile vaccine candidates into the clinic.
Partner clinical development and manufacturing of our typhoid vaccine candidate.